Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79684.870.1951%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Revolution Medicines Inc

RVMDNASDAQ
Trade with Public
Trade with Public
$210.02
-0.85-0.4%
At close: Sep 4, 5:00 PM EST
$210.50
0.480.23%
After Hours: Sep 4, 4:14 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

1S.Buy
19Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$174Upside to Avg. PT-17.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026NeedhamAmi FadiaPT RaiseBuy$240→$275
Aug 28, 2026UBSMichael YeePT RaiseBuy$220→$265
More with Benzinga EdgeGet Access

Analyst Ratings News

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price
Avi Kapoor

PRO
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved